These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23149213)

  • 1. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
    D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
    Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents.
    Palmieri D; Valentino T; D'Angelo D; De Martino I; Postiglione I; Pacelli R; Croce CM; Fedele M; Fusco A
    Oncogene; 2011 Jul; 30(27):3024-35. PubMed ID: 21339738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin mechanism of action: what's new?
    D'Incalci M
    Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of HMGA proteins in cancer cell chemoresistance.
    D'Angelo D; Mussnich P; Arra C; Battista S; Fusco A
    J Mol Med (Berl); 2017 Apr; 95(4):353-360. PubMed ID: 28293697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of trabectedin (ET-743): a unique mechanism of action.
    D'Incalci M; Galmarini CM
    Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin mechanism of action and platinum resistance: molecular rationale.
    Ray-Coquard I
    Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
    Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
    Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
    Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin in soft tissue sarcomas.
    Brodowicz T
    Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biology of ovarian cancer and trabectedin mechanism of action.
    Ray-Coquard I
    Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.
    Minuzzo M; Marchini S; Broggini M; Faircloth G; D'Incalci M; Mantovani R
    Proc Natl Acad Sci U S A; 2000 Jun; 97(12):6780-4. PubMed ID: 10841573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trabectedin for the treatment of breast cancer.
    D'Incalci M; Zambelli A
    Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.
    Uboldi S; Craparotta I; Colella G; Ronchetti E; Beltrame L; Vicario S; Marchini S; Panini N; Dagrada G; Bozzi F; Pilotti S; Galmarini CM; D'Incalci M; Gatta R
    BMC Cancer; 2017 Feb; 17(1):107. PubMed ID: 28166781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
    Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
    Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    D'Incalci M; Badri N; Galmarini CM; Allavena P
    Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
    García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
    Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro radiosensitisation by trabectedin in human cancer cell lines.
    Romero J; Zapata I; Córdoba S; Jimeno JM; López-Martín JA; Tercero JC; De La Torre A; Vargas JA; Molerón R; Sánchez-Prieto R
    Eur J Cancer; 2008 Aug; 44(12):1726-33. PubMed ID: 18501589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin.
    Chuk MK; Balis FM; Fox E
    Oncologist; 2009 Aug; 14(8):794-9. PubMed ID: 19684073
    [No Abstract]   [Full Text] [Related]  

  • 20. Trabectedin's contribution to the treatment of sarcomas.
    Blay JY
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):3-9. PubMed ID: 23638729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.